Bio-Path Holdings, Inc. (BPTH) Appoints Tara Sadeghi As Director Of Clinical Operations

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH)("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Tara Sadeghi has joined the company as Director of Clinical Operations. Reporting to Dr. Ulrich Mueller, Chief Operating Officer, Ms. Sadeghi will be responsible for all clinical activities surrounding the Company's drug development programs.

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.